What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

被引:5
|
作者
Vardar, Rukiye [1 ]
Keskin, Muharrem [2 ]
机构
[1] Ege Univ, Dept Gastroenterol, Sch Med, Izmir, Turkey
[2] Necmettin Erbakan Univ, Dept Gastroenterol, Sch Med, Konya, Turkey
关键词
Empirical PPI test; GERD; PPI trial test; NONCARDIAC CHEST-PAIN; HIGH-DOSE RABEPRAZOLE; OMEPRAZOLE TEST; PRIMARY-CARE; NEGATIVE PATIENTS; SYMPTOM RESPONSE; CROSSOVER TRIAL; DOUBLE-BLIND; LANSOPRAZOLE; ENDOSCOPY;
D O I
10.5152/tjg.2017.05
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Empirical acid suppression tests that are performed with proton pump inhibitors (PPI) are used to detect both the presence of acid-related gastrointestinal symptoms and gastroesophageal reflux disease (GERD). In comparison to other diagnostic methods, it is non-invasive, easily applicable, and cost-effective in the diagnosis of GERD. In addition to typical reflux symptoms, it can also be used for diagnostic purposes in patients with non-cardiac chest pain (NCCP). If the symptom response is 50% and above when obtained using the PPI test in patients with NCCP, it can be considered as positive and the treatment should be continued sensitivity of the PPI test in patients with typical symptoms of GERD is 27%-89%, while its specificity is 35%-83%. Although there are differences related to the duration and dosage of the PPI test, a significant difference has not been found according to the type of PPI. When PPI test sensitivity and specificity were calculated by cumulatively evaluating the data regarding the PPI test in the literature, a sensitivity of 82.3% and specificity of 51.5% was obtained. It has been found that high doses of PPI were mostly used in studies, and the duration of the median test was 14 days. As a result, the sensitivity of PPI trial test is good, but the specificity is low in the diagnosis of GERD in patients with typical reflux symptoms.
引用
收藏
页码:S12 / S15
页数:4
相关论文
共 50 条
  • [31] Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors
    Monaco, Luigi
    Brillantino, Antonio
    Torelli, Francesco
    Schettino, Michele
    Izzo, Giuseppe
    Cosenza, Angelo
    Di Martino, Natale
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (03) : 334 - 338
  • [32] Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease
    Kahrilas, Peter J.
    Hughes, Nesta
    Howden, Colin W.
    GUT, 2011, 60 (11) : 1473 - 1478
  • [33] Evaluation of efficacy of proton pump inihibitors in refractory gastroesophageal reflux disease
    Kim, Eun Hye
    Lee, Donghwan
    Park, Kyungsoo
    Chung, Hyunsoo
    Lee, Hyuk
    Park, Jun Chul
    Shin, Sung Kwan
    Lee, Sang Kil
    Chung, Jae Bock
    Lee, Yong Chan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 290 - 290
  • [34] A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease
    Sierra-Arango, Fernando
    Castano, D. M.
    Forero, Jennifer D.
    Perez-Riveros, Erika D.
    Duarte, Gerardo Ardila
    Botero, Maria L.
    Cardenas, Andres
    De la Hoz-Valle, Jose
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 2019
  • [35] Gastroesophageal reflux disease management and chronic use of proton pump inhibitors
    Howland, Anne M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2023, 36 (12):
  • [36] Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study)
    Lu, Bin
    Zhang, Ling
    Wang, Jiangbin
    Wang, Bangmao
    Zou, Xiaoping
    Fei, Guijun
    Chen, Dongfeng
    Wang, Xuehong
    Wu, Bin
    Zou, Duowu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (10) : 1722 - 1727
  • [37] The Impact of Gastroesophageal Reflux Disease and Proton Pump Inhibitor Use on the Risk of Repeat Catheter Ablation for Atrial Fibrillation
    Cai, Jennifer X.
    Algara, Miguel
    Lo, Wai-Kit
    Kapur, Sunil
    Chan, Walter W.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (06)
  • [38] Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy
    Kawara, Fumiaki
    Fujita, Tsuyoshi
    Morita, Yoshinori
    Uda, Atsushi
    Masuda, Atsuhiro
    Saito, Masaya
    Ooi, Makoto
    Ishida, Tsukasa
    Kondo, Yasuyuki
    Yoshida, Shiei
    Okuno, Tatsuya
    Yano, Yoshihiko
    Yoshida, Masaru
    Kutsumi, Hiromu
    Hayakumo, Takanobu
    Yamashita, Kazuhiko
    Hirano, Takeshi
    Hirai, Midori
    Azuma, Takeshi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (11) : 2060 - 2067
  • [39] The Relationship Between Type 2 Diabetes Mellitus and Failure to Proton Pump Inhibitor Treatment in Gastroesophageal Reflux Disease
    Hershcovici, Tiberiu
    Jha, Lokesh K.
    Gadam, Rakshith
    Cui, Haiyan
    Gerson, Lauren
    Thomson, Stephen
    Fass, Ronnie
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (08) : 662 - 668
  • [40] Gastro-Oesophageal Reflux Disease Beyond Proton Pump Inhibitor Therapy
    Hershcovici, Tiberiu
    Fass, Ronnie
    DRUGS, 2011, 71 (18) : 2381 - 2389